Seminars in Hematology
Volume 44 , Pages 1-3 , January 2007

Introduction

  • Elias Jabbour
    • ,
  • Hagop Kantarjian

      Affiliations

    • Corresponding Author InformationAddress correspondence to Hagop Kantarjian, MD, Department of Leukemia, Unit 428, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030.

References 

  1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164–172
  2. Goldman JM, Melo JV. Chronic myeloid leukemia—Advances in biology and new approaches to treatment. N Engl J Med. 2003;349:1451–1464
  3. Quintas-Cardama A, Cortes JE. Chronic myeloid leukemia: Diagnosis and treatment. Mayo Clin Proc. 2006;81:973–988
  4. Barnes DJ, Melo JV. Cytogenetic and molecular genetic aspects of chronic myeloid leukaemia. Acta Haematol. 2002;108:180–202
  5. Kantarjian HM, Talpaz M, O’Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-α: Follow-up results. Clin Cancer Res. 2002;8:2177–2187
  6. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood. 2002;99:1928–1937
  7. Kantarjian HM, Cortes J, O’Brien S, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood. 2002;99:3547–3553
  8. Kantarjian HM, O’Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590–1595
  9. O’Brien SG, Guilhot F, Larson RA, et al. IRIS investigators Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004
  10. Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423–1432
  11. Druker BJ, Guilhot F, O’Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417
  12. Kantarjian HM, Talpaz M, O’Brien S, et al. Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic phase chronic myelogenous leukemia. Blood. 2006;108:1835–1840
  13. Roy L, Guilhot J, Kranhke T, et al. Survival advantage from imatinib compared to the combination interferon-α plus cytarabine in chronic phase CML: Historical comparison between two phase 3 trials. Blood. 2006;108:1478–1484
  14. Kantarjian H, Talpaz M, O’Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia. Blood. 2004;103:2873–2878
  15. Hughes TP, Branford S, Matthews J, et al. Trial of higher dose imatinib with selective intensification in newly diagnosed CML patients in chronic phase. Blood. 2003;102:31a;(abstr 95)
  16. Cortes J, Giles F, Salvado A, et al. High-dose (HD) imatinib in patients with previously untreated chronic myeloid leukemia (CML) in early chronic phase (CP): Preliminary results of a multicenter community based trial. J Clin Oncol. 2005;23:564a;(suppl 16, abstr 6518)
  17. Rosti G, Martinelli G, Castagnetti F, et al. Imatinib 800 mg: Preliminary results of a phase II trial of the GIMEMA CML Working Party in intermediate Sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high Sokal risk patients. Blood. 2005;106:320a;(abstr 1098)
  18. Aoki E, Kantarjian H, O’Brien S, et al. High-dose imatinib mesylate treatment in patients (pts) with untreated early chronic phase (CP) chronic myeloid leukemia (CML): 2.5-year follow-up. J Clin Oncol. 2006;24:6535;(suppl 18, abstr)
  19. Guilhot F. Sustained durability of response plus high rates of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP) treated with (IM) therapy: Update from the IRIS study. Blood. 2004;104:10a;(abstr)
  20. Silver RT, Talpaz M, Sawyers CL, et al. Four years of follow-up of 1027 patients with late chronic phase (L-CP), accelerated phase (AP), or blast crisis (BC) chronic myeloid leukemia (CML) treated with imatinib in three large phase II trials. Blood. 2004;104:23;(abstr)
  21. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876–880
  22. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome–positive leukaemia to STI571: A prospective study. Lancet. 2002;359:487–491
  23. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276–283
  24. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190–2196
  25. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767–1773
  26. Donato NJ, Wu JY, Stapley J, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. 2004;64:672–677
  27. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690–698
  28. von Bubnoff N, Peschel C, Duyster J. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): A targeted oncoprotein strikes back. Leukemia. 2003;17:829–838
  29. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399–401
  30. O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500–4505
  31. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531–2541
  32. Hochhaus A, Kantarjian H, Baccarani F, et al. Dasatinib in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to imatinib: Results of the CA180013 ’START-C’ study. J Clin Oncol. 2006;24:6508;(suppl 18, abstr)
  33. Talpaz M, Apperley JF, Kim DW, et al. Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study. J Clin Oncol. 2006;24:6526;(suppl 18, abstr)
  34. Coutre S, Martinelli G, Dombret H, et al. Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 ‘START-L’ study. J Clin Oncol. 2006;24:6528;(suppl 18, abstr)
  35. Cortes JE, Kim DW, Rosti G, et al. Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 ‘START-B’ study. J Clin Oncol. 2006;24:6529;(suppl 18, abstr)
  36. Shah NP, Rousselot P, Pasquini R, et al. Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib (Results of CA180017 START-R randomized trial). J Clin Oncol. 2006;24:6507;(suppl 18, abstr)
  37. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome–positive ALL. N Engl J Med. 2006;354:2542–2551
  38. Kantarjian HM, Gattermann N, O’Brien SG, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib resistant and intolerant patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP). J Clin Oncol. 2006;24:6534;(suppl 18, abstr)
  39. Le Coutre PD, Ottmann O, Gatterman N, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with chronic myelogenous leukemia (CML) in accelerated phase (AP). J Clin Oncol. 2006;24:6531;(suppl 18, abstr)
  40. Giles FJ, Larson R, Le Coutre P, et al. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). J Clin Oncol. 2006;24:6536;(suppl 18, abstr)
  41. Carter TA, Wodicka LM, Shah NP, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A. 2005;102:11011–11016
  42. Jabbour E, Cortes J, Kantarjian HM, et al. Allogenic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood. 2006;108:1421–1423

PII: S0037-1963(06)00254-X

doi: 10.1053/j.seminhematol.2006.12.001

Seminars in Hematology
Volume 44 , Pages 1-3 , January 2007

Article Tools